Drug Profile


Alternative Names: B-1939; B-1939 mesylate; E 7386; E-7389; ER-086526; Eribrin; Eribulin mesylate; Halaven; NSC-707389

Latest Information Update: 30 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Eisai Co Ltd; Harvard University
  • Developer Asan Medical Center; Eisai Co Ltd; Emory University; Merck & Co; National Cancer Institute (USA); PIQUR Therapeutics
  • Class 2 ring heterocyclic compounds; Antineoplastics; Cyclic ethers; Furans; Ketones; Macrocyclic compounds; Small molecules
  • Mechanism of Action Apoptosis stimulants; Cadherin modulators; Receptor protein-tyrosine kinase modulators; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Soft tissue sarcoma
  • Phase III Non-small cell lung cancer
  • Phase I/II Bladder cancer
  • Phase I Cancer; Solid tumours
  • Discontinued Prostate cancer

Most Recent Events

  • 27 Jun 2017 Eisai temporarily withdraws new drug application for eribulin in China
  • 22 Jun 2017 Eribulin mesylate licensed to Ewopharma for commercialisation in Bulgaria, Croatia, Estonia, Hungary, Latvia, Lithuania, Poland, Romania and Slovenia, Bosnia & Herzegovina and Serbia
  • 27 Feb 2017 Launched for Breast cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in South Africa (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top